This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation No 596/2014 which is part of English law by virtue of the European (Withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.
30 October 2026
("EDX Medical" or the "Group" or "Company")
LEADING INDUSTRY FIGURE APPOINTED CHAIR
CAMBRIDGE, UK: EDX Medical Group plc, which develops and supplies innovative digital diagnostic products and services to improve the early detection and treatment of major diseases, announces the Company has appointed Professor Michael John Owen, a leading life sciences industry figure, as its non-executive Chairman.
Professor Owen succeeds with immediate effect non-executive chairman Jason Holt who has led the board since the company's inception and is stepping down owing to a need for increasing focus on other Chairman roles and charitable interests.
Professor Owen is a highly experienced R&D executive and non-executive director with a proven track record of global executive leadership. He has a broad knowledge of the Pharma industry and of the finance community that supports life sciences. He is currently an independent member of a number of boards of biotech companies and an adviser to several investment partnerships. Professor Owen has also held senior executive positions, notably as co-founder and Chief Scientific Officer of Kymab Limited, a biopharmaceutical company, ultimately acquired by Sanofi, as well as several senior leadership positions at GlaxoSmithKline.
Professor Owen commented: "I am delighted to be joining and chairing the board of EDX Medical, a company that has a very clear vision of the future for medical diagnostics - a burgeoning sector at UK, European and global levels. The EDX team has built a hugely impressive portfolio of class-leading tests and services and is well placed to become an exemplar company in the diagnostics arena. I am looking forward to Jason passing me the Chair baton and developing further the excellent work done by him and the Board to date."
Professor Sir Chris Evans, founder of EDX Medical, commented: "We are thrilled to welcome Mike Owen to EDX Medical. He is an outstanding figure in the industry and brings tremendous commercial, scientific and governance experience which will be a great asset to the Company. I would also like express my personal gratitude to Jason for his contribution to the Company as a director and chairman. He joined EDX in its earliest days and put an enormous amount of effort and leadership into developing the Company."
Jason Holt commented: "I am very proud of what the Company has achieved in a short space of time, moving rapidly from a start-up to an AIM-listed public company with a very admirable diagnostics portfolio. We have made an excellent choice of new chairman. I am pleased to be stepping down to make way for Mike. It affords me more time for my other Chairmanships at a critical time where growth in these strategic organisations intersects with the national economy. I wish the EDX team under Mike's Chairmanship all the very best as the Company moves forward."
Additional information
Professor Michael John Owen, aged 75, holds no ordinary shares in the Company.
Professor Owen holds or has held the following directorships and/or partnerships in the past five years:
Current:
Ossianix Inc (Chairman)
Sareum Holdings plc
(Chair of Remuneration committee and member of Audit committee)
NovalGen Ltd
Istesso Ltd
Club Cricket Organisation Limited
Past directorships/partnerships in last five years:
Zealand Pharma A/S
ReNeuron Group Limited
Gamma Delta Therapeutics Limited
Iksuda Therapeutics Limited
Professor Owen was a director of ReNeuron Group Limited between December 2015 and March 2025. ReNeuron Group Limited entered into administration on 20 March 2024 and exited administration on 17 March 2025 following confirmation that the purpose of administration had been achieved and that creditor claims were settled in full.
There is no further information required to be disclosed under Schedule Two, paragraph (g) of the AIM Rules for Companies.
Contacts
|
Canaccord Genuity Limited (Nominated Adviser and Broker) |
|
|
Stuart Andrews |
+44 (0) 20 7523 8318 |
|
Media House International |
|
|
Ramsay Smith Gary McQueen |
+44 (0)7788 414856 + 44 (0)7834 694609 |
|
IFC Advisory (Investor Relations) |
|
|
Graham Herring Tim Metcalfe |
+44 (0) 203 934 6630 |
About EDX Medical Group plc
The EDX Medical Group plc is listed on the AIM market (TIDM: EDX).
EDX Medical was founded by Professor Sir Christopher Evans, OBE, a medical and life sciences entrepreneur with more than 30 years of experience, together with CEO, Dr Mike Hudson.
By translating clinical insights into pragmatic solutions combining advanced biological and digital technologies, EDX Medical seeks to cost effectively improve the detection and characterisation of disease to personalise treatment in a timely fashion. Early disease detection and biologically based personal treatment optimisation is considered to be the most impactful way of improving patient outcomes, reducing deaths and lowering the cost of healthcare globally.
EDX Medical Group provides doctors, hospitals and insurers/payers with access to a portfolio of the best clinical diagnostics products and services. The Company operates its own facilities in Cambridge, UK, and has strategic product and technology partnerships with organisations such as Thermo Fisher EMEA Ltd, a world leader in supplying life sciences solutions and services.